SERVICES AND RESULTS
The In finite translation methodology (a class of NAMs – new approach methodologies) is based on the in vitro monitoring of subcellular and cellular responses (using cellular devices) that are translated into a digital twin by µIND engine, deriving early Mode-of-Action, that finally enables mechanistic prediction of disease evolution several months or even years into the future.
The key benefit of using our In finite technology is to gain insight into potential long-term hazard
much faster than by any other testing, including any organoid-based NAMs and especially any animal
testing.
Does my material trigger any of the following endpoints:
| Endpoint | Platform | Maturity Level | Delivery Time | Type of Info |
|---|---|---|---|---|
| Chronic Inflammation | Lung | Automated Service | 1 Week | Dose + Time Dependence + MoA Indications |
| Cancerogenicity | Lung | Service Prototype + | 1-2 Months | Dose + Time Dependence + MoA Indications |
| Neurodegenerative Diseases | Brain + Lung | R&D, Service Prototype + | 2 Weeks - 3 Months | Dose + Time Evolution + MoA |
| Bone Osteolysis | Bone | Service Prototype + | 2 Weeks - 1 Month | Dose + Time Evolution + MoA |
| R&D on Demand | Any Combination of Above + Expanded (40+) Subcellular | R&D + Cellular Event Tracking | - | - |
Interested in our services?
REQUEST A QUOTE
We adapt our approach to your needs by rapidly identifying and solving any possible obstacle in a joint conversation.